BMAL1 antibody | knockout validation | Cell Signaling 14020

This is a knockout-validated antibody summary, based on the publication "Bmal1 Downregulation Worsens Critical Limb Ischemia by Promoting Inflammation and Impairing Angiogenesis", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

BMAL1 antibody | knockout validation | Cell Signaling 14020 figure 1
Figure 1. Protein expression level of BAML1 and VEGF in hindlimb ischemia (HLI) and non-HLI limbs measured by western blot. From [1].
Antibody information

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: BMAL1

Catalog number: 14020

Summary: Rabbit monoclonal antibody against a synthetic peptide corresponding to residues surrounding Gly552 of human BMAL1 protein. Reacts with human, mouse and rat. Suitable for western blot, immunoprecipitation (IP) and Chromatin IP.

Validation Method

Western blot

Sample

WT and Bmal1−/− mice lower limb muscles.

Blocking agent

5% milk in PBS–Tween-20 buffer (PBST) for 1 h at room temperature.

Primary incubation

0.5 μg/ml overnight at 4°C.

Secondary incubation

Peroxidase-conjugated with secondary antibodies at room temperature for 1.5 h.

Detection

ECL western blotting substrate (Bio-Rad).

References
  1. Xu L, Liu Y, Cheng Q, Shen Y, Yuan Y, Jiang X, et al. Bmal1 Downregulation Worsens Critical Limb Ischemia by Promoting Inflammation and Impairing Angiogenesis. Front Cardiovasc Med. 2021;8:712903 pubmed publisher